

Annex B: Terminology Used in Basis of Preparation

Terminology and rounding

Terms used in the financial forecast update paper have the meanings described below, and are relevant to Gavi's Programme Funding Policy. Given the nature of the COVAX Facility and the current Board mandate, not all concepts are applicable to COVAX.

a) Assured Resources comprise:

- Cash and investments of Gavi, in the amount that exceeds the Cash and Investments Reserve (see (d) below)
- Expected proceeds from IFFIm, based on existing donor pledges
- Any other contributions that are contingent on programmatic expenditure included in the expenditure forecast (ring-fenced funding)
- Confirmed direct contributions to Gavi that are pledged under already-signed agreements or otherwise confirmed in writing
- Projected investment income

b) Allowance for Further Direct Contributions (for the purpose of approving funding decisions): An allowance for further expected direct contributions from existing donors who have not confirmed their pledges for each year, based on current overall contribution levels. The allowance is mandated by the Programme Funding Policy and is important towards enabling programme funding decisions to be made while pledges have yet to be completed for particular years. The allowance assumes that in years where currently confirmed direct contributions total less than the current level, further contributions will bring the total to that level.

c) Qualifying Resources: The sum of Assured Resources and the Allowance for Further Direct Contributions (i.e. (a) plus (b) above).

d) Cash and Investments Reserve: The reserve required by the Programme Funding Policy to be maintained at a minimum equalling eight months (currently nine) of expected annual expenditures.

Rounding:

In text and tables throughout the financial forecast paper, numbers may be rounded to shorter, significant numbers in order to enhance readability and ease of reference. Individual numbers and the totals they comprise are rounded independently. Consequently, the individual numbers may appear not to sum to their total because of rounding.

Vaccine programme acronyms

Pneumo / PCV: Pneumococcal conjugate vaccine

<https://www.gavi.org/types-support/vaccine-support/pneumococcal>

IPV / Polio: Inactivated polio vaccine

<https://www.gavi.org/types-support/vaccine-support/inactivated-polio-vaccine>

Rota: Rotavirus vaccine

<https://www.gavi.org/types-support/vaccine-support/rotavirus>

Yellow Fever: Yellow Fever vaccine routine programme

<https://www.gavi.org/types-support/vaccine-support/yellow-fever>

HPV: Human Papillomavirus vaccine

<https://www.gavi.org/types-support/vaccine-support/human-papillomavirus>

Penta: Pentavalent vaccine (protecting against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b)

<https://www.gavi.org/types-support/vaccine-support/pentavalent>

Typhoid (TCV): Typhoid conjugate vaccine

<https://www.gavi.org/types-support/vaccine-support/typhoid>

Measles-Rubella (MR): Measles-Rubella vaccine

<https://www.gavi.org/types-support/vaccine-support/measles-and-measles-rubella>

VIS vaccines include Cholera, DTP-containing boosters, HepB birth dose, Multivalent Men, Rabies PEP

Men A: Meningitis A vaccine routine programme

<https://www.gavi.org/types-support/vaccine-support/meningitis-a>

Malaria (cost-share mechanism) is a mechanism put in place to secure the continued manufacture of GSK's RTS,S antigen once the donated doses for the Malaria Vaccine Implementation Programme are utilised in advance of Gavi decision on whether to fund a malaria vaccine programme (post WHO SAGE recommendation). *For further details, refer to Dec. 2019 Board decision.*

Other vaccines in expenditure estimate tables refer to:

Measles (<https://www.gavi.org/types-support/vaccine-support/measles-and-measles-rubella>),

Japanese encephalitis (JE) (<https://www.gavi.org/types-support/vaccine-support/japanese-encephalitis>),

Ebola (<https://www.gavi.org/news/media-room/gavi-board-approves-new-ebola-vaccine-programme>),

Hexavalent (DTwP-HepB-IPV-Hib) vaccines and stockpiles for outbreak response Yellow fever, Meningitis and Ebola vaccines.